Product Description
Cirmtuzumab targets a molecule called ROR1 that normally is used only by embryonic cells during early development, but which is abnormally exploited by cancer cells to promote tumor growth and spread, otherwise known as metastasis. (Sourced from: https://health.ucsd.edu/news/releases/pages/2018-06-01-phase-1-trial-finds-experimental-drug-safe-in-treating-chronic-lymphocytic-leukemia.aspx)
Mechanisms of Action: ROR1 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous,Oral
FDA Designation: Orphan Drug - Chronic Leukemia|Chronic Lymphoid Leukemia|Leukemia|Lymphoid Leukemia|Lymphoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oncternal Therapeutics
Company Location: SAN DIEGO CA 92130
Company CEO: James B. Breitmeyer
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Lymphoma
Phase 2: B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Mantle-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001547-25 | P3 |
Active, not recruiting |
Lymphoma |
2027-02-20 |
|
| Venetoclax | P2 |
Active, not recruiting |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2025-07-22 |
|
| CIRM-0001 (CIRLL) | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia|B-Cell Marginal Zone Lymphoma |
2024-09-25 |
|
| CIRM-0001 | P2 |
Recruiting |
Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell |
2019-04-01 |